Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

Exclusion Criteria

• •Patients homozygous for UGT1A1\*28 or UGT1A1\*6 alleles.
• •Patients known or suspected intolerance or hypersensitivity to main ingredient or any of the excipients of SNB-101.
• •Patients with unintentional weight loss \>10% within 3 months prior to screening.
• •Patients who are on dialysis.
• •Patients who are positive for HIVs.
• •Patients with a QT interval with Fridericia's correction outside of normal.
• •Patients with intestinal palsy or bowel obstruction.
• •Patients with chronic inflammatory bowel disease.
• •Patients who may require administration of neuromuscular blockers, peripheral muscle relaxants, etc. during the study.
• •Patients who may require lapatinib during the study.
• •Patients who may require attenuated vaccine during the study.
• •Patients who are taking any medication that in the judgement of the investigator could have an effect on the action of SNB-101.
• •Patients unable to participate in the study as judged by the investigator.